ArticlemedRxiv : the preprint server for health sciences2025
Rapid Discrimination of High-Grade Prostate Cancer Using Label-Free Fluorescence Lifetime Measurements.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
Abstract
Purpose: Histologic evaluation of prostatic needle biopsies is essential for prostate cancer (PCa) diagnosis and treatment planning, yet tissue targeting remains suboptimal despite MRI-guided Bx procedures. This pilot study investigates the use of label-free Fluorescence Lifetime Imaging (FLIm) for real-time biopsy guidance. Using ex vivo specimens, we assess FLIm's preliminary efficacy in discriminating malignant from benign prostate tissue. Materials and Methods: Twenty patients undergoing prostate biopsy were enrolled. FLIm measurements were performed immediately after sample collection using a custom fiber-optic probe. Optical parameters from 4 spectral bands associated with distinct endogenous fluorophores including structural proteins and metabolic cofactors (e.g. NADH, FAD) were extracted and labeled based on histological annotation. Data were analyzed to characterize tissue-type differences and train and evaluate a classifier to distinguish malignancy. Results: Separation between benign tissue and Gleason grade ≥4 PCa was achieved using just 2 of 56 FLIm-derived parameters. A Support Vector Machine classifier using all parameters achieved a ROC of 0.88 in identifying grade 4 PCa. A reduced lifetime value in the NADH-associate band, likely due to increased free NADH from upregulated glycolysis, supports the biochemical basis for optical differentiation. Conclusions: FLIm shows significant potential for high-grade PCa identification. The single-fiber approach requires minimal modification for integration into current biopsy tools, supporting its feasibility for clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.